New Cell test To Assess Responsiveness to Iressa 

The Harvard Medical School - Partners HealthCare Center for Genetics and Genomics (HPCGG) is offering a test to guide the treatment of certain
The known as EGFR Kinase Domain Sequencing detects mutations in the tyrosine kinase portion of the   epidermal growth factor receptor (EGFR).   "This gene mutation is present in a subset of non-small cell lung cancers, most commonly adenocarcinomas and bronchoalveolar carcinomas arising in nonsmokers. When the mutation is present, it is associated with a response to the anti-cancer drug Iressa (gefitinib). Iressa works by blocking the function of the mutant EGFR protein that these cancer cells need to survive and proliferate."


Home  Page